Overview
- Argus cut Novo Nordisk to Hold on Dec. 8, citing GLP‑1 market-share losses, U.S. price concessions, generics risk, and underwhelming semaglutide data in Alzheimer’s.
- The company has filed an sNDA for a 7.2 mg semaglutide dose, with management expecting an expedited FDA review within 1–2 months after filing acceptance under the CNPV program.
- Reuters reported Ozempic will be available in India this month, opening a large diabetes and weight-loss market with significant growth potential.
- Berenberg’s Kerry Holford reaffirmed a Buy on Dec. 5, and roughly 60% of covering analysts rate the stock Buy with a median price target near $62.
- A Seeking Alpha column published today argues the shares are undervalued versus peers and assigns a modest Buy rating.